NASDAQ:NK - NantKwest Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.97 +0.05 (+1.28 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$3.97
Today's Range$3.91 - $4.05
52-Week Range$3.41 - $8.45
Volume141,524 shs
Average Volume116,908 shs
Market Capitalization$310.01 million
P/E Ratio-3.31
Dividend YieldN/A
Beta2.83

About NantKwest (NASDAQ:NK)

NantKwest logoNantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Receive NK News and Ratings via Email

Sign-up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NK
CUSIPN/A
Phone858-633-0300

Debt

Debt-to-Equity Ratio0.01
Current Ratio6.54
Quick Ratio6.54

Price-To-Earnings

Trailing P/E Ratio-3.31
Forward P/E Ratio-2.70
P/E GrowthN/A

Sales & Book Value

Annual Sales$50,000.00
Price / Sales6,200.35
Cash FlowN/A
Price / CashN/A
Book Value$2.57 per share
Price / Book1.54

Profitability

EPS (Most Recent Fiscal Year)($1.20)
Net Income$-96,420,000.00
Net Margins-254,917.94%
Return on Equity-43.71%
Return on Assets-37.53%

Miscellaneous

Employees139
Outstanding Shares78,090,000

NantKwest (NASDAQ:NK) Frequently Asked Questions

What is NantKwest's stock symbol?

NantKwest trades on the NASDAQ under the ticker symbol "NK."

How were NantKwest's earnings last quarter?

NantKwest (NASDAQ:NK) announced its quarterly earnings data on Monday, March, 12th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter. The biotechnology company earned $0.01 million during the quarter. NantKwest had a negative return on equity of 43.71% and a negative net margin of 254,917.94%. View NantKwest's Earnings History.

What price target have analysts set for NK?

2 brokers have issued 12-month price targets for NantKwest's stock. Their predictions range from $3.00 to $3.00. On average, they expect NantKwest's stock price to reach $3.00 in the next twelve months. View Analyst Ratings for NantKwest.

Who are some of NantKwest's key competitors?

Who are NantKwest's key executives?

NantKwest's management team includes the folowing people:
  • Dr. Patrick Soon-Shiong, Exec. Chairman and Chief Exec. Officer (Age 65)
  • Dr. Barry J. Simon, Pres, Chief Admin. Officer and Exec. Director (Age 53)
  • Ms. Sonja Nelson, Chief Accounting Officer (Age 45)
  • Mr. Richard J. Tajak M.B.A., Chief Financial Officer (Age 65)
  • Mr. David J. Pyrce M.B.A., Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 61)

When did NantKwest IPO?

(NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

Has NantKwest been receiving favorable news coverage?

News articles about NK stock have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. NantKwest earned a coverage optimism score of 0.06 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 44.99 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are NantKwest's major shareholders?

NantKwest's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.27%), Millennium Management LLC (0.20%), Alps Advisors Inc. (0.13%), JPMorgan Chase & Co. (0.06%), DekaBank Deutsche Girozentrale (0.04%) and A.R.T. Advisors LLC (0.04%). Company insiders that own NantKwest stock include Barry J Simon, John C Thomas and Steve Gorlin. View Institutional Ownership Trends for NantKwest.

Which major investors are selling NantKwest stock?

NK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc. and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for NantKwest.

Which major investors are buying NantKwest stock?

NK stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, A.R.T. Advisors LLC, Alps Advisors Inc. and JPMorgan Chase & Co.. View Insider Buying and Selling for NantKwest.

How do I buy shares of NantKwest?

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NantKwest's stock price today?

One share of NK stock can currently be purchased for approximately $3.97.

How big of a company is NantKwest?

NantKwest has a market capitalization of $310.01 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,420,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. NantKwest employs 139 workers across the globe.

How can I contact NantKwest?

NantKwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]


MarketBeat Community Rating for NantKwest (NK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  324
MarketBeat's community ratings are surveys of what our community members think about NantKwest and other stocks. Vote "Outperform" if you believe NK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NantKwest (NASDAQ:NK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for NantKwest in the last 12 months. Their average twelve-month price target is $3.00, suggesting that the stock has a possible downside of 24.43%. The high price target for NK is $3.00 and the low price target for NK is $3.00. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.501.672.002.00
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.00$3.50$5.3333$5.3333
Price Target Upside: 24.43% downside29.29% downside7.74% upside9.30% downside

NantKwest (NASDAQ:NK) Consensus Price Target History

Price Target History for NantKwest (NASDAQ:NK)

NantKwest (NASDAQ:NK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017Raymond JamesReiterated RatingHoldMediumView Rating Details
8/14/2017CitigroupSet Price TargetSell$3.00LowView Rating Details
5/8/2017Jefferies GroupSet Price TargetHold$4.00MediumView Rating Details
3/17/2017FBR & CoReiterated RatingOutperform ➝ Outperform$22.00 ➝ $9.00LowView Rating Details
8/19/2016Canaccord GenuityReiterated RatingBuy$18.00N/AView Rating Details
8/17/2016Piper Jaffray CompaniesReiterated RatingOverweight$32.00 ➝ $23.00N/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

NantKwest (NASDAQ:NK) Earnings History and Estimates Chart

Earnings by Quarter for NantKwest (NASDAQ:NK)

NantKwest (NASDAQ:NK) Earnings Estimates

2018 EPS Consensus Estimate: ($1.57)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.35)($0.35)($0.35)
Q2 20181($0.38)($0.38)($0.38)
Q3 20181($0.42)($0.42)($0.42)
Q4 20181($0.42)($0.42)($0.42)

NantKwest (NASDAQ NK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018Q4 2017($0.31)$0.01 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.30)$0.01 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.32)($0.29)$0.01 million$0.01 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.39)($0.30)$0.01 million$0.01 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)$0.01 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.39)$0.01 millionViewN/AView Earnings Details
8/15/2016Q2($0.35)($0.41)$0.10 million$0.01 millionViewN/AView Earnings Details
5/16/2016Q1($0.2370)($0.38)$0.10 million$0.01 millionViewN/AView Earnings Details
3/30/2016Q4 2015($0.97)$0.01 millionViewN/AView Earnings Details
11/12/2015Q3 2015($0.07)($0.55)$0.10 million$0.01 millionViewN/AView Earnings Details
9/10/2015Q2 2015($1.29)$0.09 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

NantKwest (NASDAQ:NK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

NantKwest (NASDAQ NK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 72.30%
Institutional Ownership Percentage: 16.10%
Insider Trading History for NantKwest (NASDAQ:NK)
Institutional Ownership by Quarter for NantKwest (NASDAQ:NK)

NantKwest (NASDAQ NK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2018Steve GorlinDirectorSell81,743$4.05$331,059.15246,280View SEC Filing  
5/15/2018Steve GorlinDirectorSell26,835$4.13$110,828.55246,280View SEC Filing  
9/13/2017Steve GorlinDirectorSell39,604$5.93$234,851.72246,280View SEC Filing  
9/12/2017Steve GorlinDirectorSell103,841$6.04$627,199.64375,002View SEC Filing  
6/20/2017Steve GorlinDirectorSell40,000$7.78$311,200.00409,725View SEC Filing  
11/25/2016John C ThomasDirectorSell6,168$7.50$46,260.00309,621View SEC Filing  
11/23/2016John C ThomasDirectorSell20,000$7.50$150,000.00322,789View SEC Filing  
9/8/2016Barry J SimonInsiderSell32,000$7.49$239,680.003,334,906View SEC Filing  
12/10/2015Angela WilsonCFOBuy3,265$15.33$50,052.453,265View SEC Filing  
8/21/2015Steve GorlinDirectorSell450,000$23.00$10,350,000.00455,713View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NantKwest (NASDAQ NK) News Headlines

Source:
DateHeadline
Steve Gorlin Sells 26,835 Shares of NantKwest (NK) StockSteve Gorlin Sells 26,835 Shares of NantKwest (NK) Stock
www.americanbankingnews.com - May 17 at 8:34 PM
Insider Selling: NantKwest (NK) Director Sells 81,743 Shares of StockInsider Selling: NantKwest (NK) Director Sells 81,743 Shares of Stock
www.americanbankingnews.com - May 17 at 7:57 PM
NantKwest (NK) Upgraded to Hold at ValuEngineNantKwest (NK) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 11:36 PM
NantKwest (NK) Given Consensus Rating of "Hold" by AnalystsNantKwest (NK) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 29 at 5:30 AM
Head-To-Head Contrast: NantKwest (NK) and Applied Genetic Technologies (AGTC)Head-To-Head Contrast: NantKwest (NK) and Applied Genetic Technologies (AGTC)
www.americanbankingnews.com - April 28 at 5:08 PM
NantKwest (NK) Downgraded to Hold at Zacks Investment ResearchNantKwest (NK) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 18 at 8:34 PM
NantKwest (NK) Upgraded by BidaskClub to SellNantKwest (NK) Upgraded by BidaskClub to Sell
www.americanbankingnews.com - April 17 at 9:57 AM
NantKwest (NK) Downgraded by BidaskClubNantKwest (NK) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 5:18 PM
BidaskClub Lowers NantKwest (NK) to SellBidaskClub Lowers NantKwest (NK) to Sell
www.americanbankingnews.com - April 12 at 6:14 PM
NantKwest (NK) Stock Rating Lowered by BidaskClubNantKwest (NK) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 10 at 3:25 PM
Citigroup Analysts Give NantKwest (NK) a $3.00 Price TargetCitigroup Analysts Give NantKwest (NK) a $3.00 Price Target
www.americanbankingnews.com - April 10 at 11:28 AM
Zacks Investment Research Lowers Nantkwest (NK) to HoldZacks Investment Research Lowers Nantkwest (NK) to Hold
www.americanbankingnews.com - April 6 at 6:29 PM
Nantkwest Inc (NK) Receives Consensus Rating of "Hold" from AnalystsNantkwest Inc (NK) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 4 at 5:31 AM
Nantkwest (NK) Rating Lowered to Hold at Zacks Investment ResearchNantkwest (NK) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 5:48 PM
Form 4 NantKwest, Inc. For: Mar 23 Filed by: Nelson SonjaForm 4 NantKwest, Inc. For: Mar 23 Filed by: Nelson Sonja
www.streetinsider.com - March 27 at 9:53 AM
Nantkwest (NK) Upgraded by BidaskClub to HoldNantkwest (NK) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - March 24 at 12:28 PM
Nantkwest Inc (NK) Expected to Earn Q1 2018 Earnings of ($0.35) Per ShareNantkwest Inc (NK) Expected to Earn Q1 2018 Earnings of ($0.35) Per Share
www.americanbankingnews.com - March 19 at 1:53 AM
Nantkwest Inc (NK) to Post FY2022 Earnings of ($1.23) Per Share, Jefferies Group ForecastsNantkwest Inc (NK) to Post FY2022 Earnings of ($1.23) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 16 at 4:20 PM
NantKwest to Present at Upcoming Investment and Healthcare ConferencesNantKwest to Present at Upcoming Investment and Healthcare Conferences
finance.yahoo.com - March 14 at 10:28 AM
Nantkwest (NK) Rating Increased to Sell at BidaskClubNantkwest (NK) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - February 24 at 11:18 AM
Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in GlioblastomaNantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Glioblastoma
finance.yahoo.com - February 13 at 9:08 AM
3 Stocks Under $10 That Surged Yesterday3 Stocks Under $10 That Surged Yesterday
finance.yahoo.com - February 1 at 9:15 AM
Putin says U.S. is taking 'hostile step'Putin says U.S. is taking 'hostile step'
finance.yahoo.com - February 1 at 9:15 AM
Yahoo Finance Live: Market Movers - Jan 30th, 2018Yahoo Finance Live: Market Movers - Jan 30th, 2018
finance.yahoo.com - February 1 at 9:15 AM
Nantkwest (NK) Rating Lowered to Strong Sell at BidaskClubNantkwest (NK) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - January 21 at 2:16 PM
Nantkwest Inc (NK) Receives Consensus Rating of "Hold" from BrokeragesNantkwest Inc (NK) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 19 at 5:52 AM
Nantkwest (NK) Lifted to "Buy" at Zacks Investment ResearchNantkwest (NK) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 14 at 12:38 PM
Nantkwest (NK) Upgraded to Buy at Zacks Investment ResearchNantkwest (NK) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - January 6 at 10:12 AM
ETFs with exposure to NantKwest, Inc. : December 28, 2017ETFs with exposure to NantKwest, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 3:43 PM
NantKwest, Inc. :NK-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017NantKwest, Inc. :NK-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 28 at 6:10 AM
Head to Head Review: BioCryst Pharmaceuticals (BCRX) and Nantkwest (NK)Head to Head Review: BioCryst Pharmaceuticals (BCRX) and Nantkwest (NK)
www.americanbankingnews.com - December 26 at 6:17 PM
Nantkwest Inc (NK) Given Consensus Recommendation of "Hold" by BrokeragesNantkwest Inc (NK) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 25 at 5:40 AM
Update in Lawsuit for Investors in Nantkwest Inc. (NASDAQ: NK) Shares Announced by Shareholders FoundationUpdate in Lawsuit for Investors in Nantkwest Inc. (NASDAQ: NK) Shares Announced by Shareholders Foundation
finance.yahoo.com - December 12 at 10:12 AM
Nantkwests (NK) Hold Rating Reaffirmed at Raymond James FinancialNantkwest's (NK) Hold Rating Reaffirmed at Raymond James Financial
www.americanbankingnews.com - December 11 at 11:50 AM
NantKwest, Inc. (NK) Given Consensus Recommendation of "Hold" by AnalystsNantKwest, Inc. (NK) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 30 at 5:56 AM
NantKwest, Inc. (NK) Raised to "Buy" at Zacks Investment ResearchNantKwest, Inc. (NK) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 25 at 8:10 PM
NantKwest, Inc. (NK) Given Consensus Recommendation of "Hold" by BrokeragesNantKwest, Inc. (NK) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 5 at 5:52 AM
NantKwest Becomes OversoldNantKwest Becomes Oversold
www.thestreet.com - November 2 at 6:51 AM
ETFs with exposure to NantKwest, Inc. : October 11, 2017ETFs with exposure to NantKwest, Inc. : October 11, 2017
finance.yahoo.com - October 12 at 7:28 AM
NantKwest, Inc. (NK) Given Consensus Rating of "Hold" by AnalystsNantKwest, Inc. (NK) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - October 11 at 8:49 AM
NantKwest, Inc. (NK) Upgraded by Zacks Investment Research to BuyNantKwest, Inc. (NK) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - October 11 at 6:32 AM
NantKwest (NK) and Its Peers Critical ComparisonNantKwest (NK) and Its Peers Critical Comparison
www.americanbankingnews.com - October 10 at 8:22 PM
NantKwest (NK) Announces Successful First in Human Administration of CD16 haNK Cells - StreetInsider.comNantKwest (NK) Announces Successful First in Human Administration of CD16 haNK Cells - StreetInsider.com
www.streetinsider.com - October 2 at 5:56 PM
ETFs with exposure to NantKwest, Inc. : September 26, 2017ETFs with exposure to NantKwest, Inc. : September 26, 2017
finance.yahoo.com - October 2 at 5:56 PM
NantKwest (NK) Appoints Fred Driscoll to Board - StreetInsider.com - StreetInsider.comNantKwest (NK) Appoints Fred Driscoll to Board - StreetInsider.com - StreetInsider.com
www.streetinsider.com - September 24 at 6:14 AM
NANTKWEST (NK) SHAREHOLDER ALERT – Andrews & Springer LLC is Investigating NantKwest, Inc. for Potential Breaches of Fiduciary DutyNANTKWEST (NK) SHAREHOLDER ALERT – Andrews & Springer LLC is Investigating NantKwest, Inc. for Potential Breaches of Fiduciary Duty
finance.yahoo.com - September 22 at 8:52 AM
NANTKWEST INVESTOR INVESTIGATION ALERT – Andrews & Springer LLC Is Investigating NantKwest, Inc. For Potential Breaches of Fiduciary DutyNANTKWEST INVESTOR INVESTIGATION ALERT – Andrews & Springer LLC Is Investigating NantKwest, Inc. For Potential Breaches of Fiduciary Duty
feeds.benzinga.com - September 21 at 7:13 PM
NantKwest, Inc. (NK) Receives Consensus Recommendation of "Hold" from BrokeragesNantKwest, Inc. (NK) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 16 at 6:36 AM
Insider Selling: NantKwest, Inc. (NK) Director Sells 39,604 Shares of StockInsider Selling: NantKwest, Inc. (NK) Director Sells 39,604 Shares of Stock
www.americanbankingnews.com - September 13 at 10:22 PM
NantKwest, Inc. (NK) Director Steve Gorlin Sells 103,841 SharesNantKwest, Inc. (NK) Director Steve Gorlin Sells 103,841 Shares
www.americanbankingnews.com - September 12 at 7:34 PM

SEC Filings

NantKwest (NASDAQ:NK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NantKwest (NASDAQ:NK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NantKwest (NASDAQ NK) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.